Skip to main content

Advertisement

SpringerLink
Log in

Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Bispecific single-chain antibody constructs specific for human CD3 have been extensively studied for antitumor activity in human xenograft models using severe combined immunodeficient mice supplemented with human T cells. High efficacy at low effector-to-target ratios, independence of T cell costimuli and a potent activation of previously unstimulated polyclonal T cells were identified as hallmarks of this class of bispecific antibodies. Here we studied a bispecific single-chain antibody construct (referred to as ‘bispecific T cell engager’, BiTE) in an immunocompetent mouse model. This was possible by the use of a murine CD3-specific BiTE, and a syngeneic melanoma cell line (B16F10) expressing the human Ep-CAM target. The murine CD3-specific BiTE, called 2C11x4-7 prevented in a dose-dependent fashion the outgrowth of subcutaneously growing B16/Ep-CAM tumors with daily i.v. injections of 5 or 50 μg BiTE which was most effective. Treatment with 2C11x4-7 was effective even when it was started 10 days after tumor cell inoculation but delayed treatments showed a reduction in the number of cured animals. 2C11x4-7 was also highly active in a lung tumor colony model. When treatment was started on the day of intravenous tumor cell injection, seven out of eight animals stayed free of lung tumors, and three out of eight animals when treatment was started on day 5. Our study shows that BiTEs also have a high antitumor activity in immunocompetent mice and that there is no obvious need for costimulation of T cells by secondary agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316:354–356

    Article  PubMed  CAS  Google Scholar 

  2. Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314:628–631

    Article  PubMed  CAS  Google Scholar 

  3. Kufer P, Lutterbuse R, Baeuerle PA (2004) A Revival of bispecific antibodies. Trends Biotechnol 22:238–244

    Article  PubMed  CAS  Google Scholar 

  4. Talac R, Nelson H (2000) Current perspectives of bispecific antibody-based immunotherapy. J Biol Regul Homeost Agents 14:175–181

    PubMed  CAS  Google Scholar 

  5. Baeuerle PA, Kufer P, Lutterbuse R (2003) Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther 5:413–419

    PubMed  CAS  Google Scholar 

  6. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA (2002) Extremely potent rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690–697

    Article  PubMed  CAS  Google Scholar 

  7. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Riethmuller G, Gjorstrup P, Bargou RC (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170:4397–4402

    PubMed  CAS  Google Scholar 

  8. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RCA (2000) recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098–2103

    PubMed  CAS  Google Scholar 

  9. Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, Dorken B, Bargou RC (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17:900–909

    Article  PubMed  CAS  Google Scholar 

  10. Zocher M, Baeuerle PA (2004) Bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. Mol Immunol 41:511–518

    Article  PubMed  CAS  Google Scholar 

  11. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer

  12. Offner S, Romaniuk A, Kufer P, Baeuerle PA (2005) Induction of Regular Cytolytic T Cell Synapses by Bispecific Single-Chain Antibody Constructs on MHC Class I-negative Tumor Cells. Mol Immunol

  13. Schlereth B, I Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA (2005) Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-chain Ep-CAM-/CD3-bispecific Antibody Construct. Cancer Res

  14. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35:122–128

    Article  PubMed  CAS  Google Scholar 

  15. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125:437–446

    Article  PubMed  CAS  Google Scholar 

  16. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S (2004) Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25:841–848

    PubMed  CAS  Google Scholar 

  17. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Pluckthun A, Stahel RA, Zangemeister-Wittke U (2003) A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9:2837–2848

    PubMed  CAS  Google Scholar 

  18. Adkins JC, Spencer CM (1998) Edrecolomab (monoclonal antibody 17–1A). Drugs 56:619–626; discussion 627–618

    Google Scholar 

  19. de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF (2004) ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 10:7555–7565

    Article  PubMed  Google Scholar 

  20. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, Dreier T (2002) In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100:101–110

    Article  PubMed  CAS  Google Scholar 

  21. Poncelet P, Carayon P (1985) Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J Immunol Methods 85:65–74

    Article  PubMed  CAS  Google Scholar 

  22. Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Turker A, Goldstone AH, Burnett A (1996) Leukemia-associated changes identified by quantitative flow cytometry IV CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 87:1162–1169

    PubMed  CAS  Google Scholar 

  23. Kufer P, Zettl F, Borschert K, Lutterbuse R, Kischel R, Riethmuller G (2001) Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun 1:10

    PubMed  CAS  Google Scholar 

  24. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374–1378

    Article  PubMed  CAS  Google Scholar 

  25. Mack M, Riethmuller G, Kufer PA (1995) small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021–7025

    Article  PubMed  CAS  Google Scholar 

  26. Sambrook J, Russel DW (2001) Molecular Cloning, a laboratory manual, 3rd edn. Cold Spring Habor Laboratory Press, New York

    Google Scholar 

  27. Kaufman RJ (1990) Selection and coamplification of heterologous genes in mammalian cells. Methods Enzymol 185:537–566

    Article  PubMed  CAS  Google Scholar 

  28. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, da Silva A, Baeuerle PA (2005) MT110: A Novel Bispecific Single-chain Antibody Construct with High Efficacy in Eradicating Established Tumors. Mol Immunol

  29. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125:200–205

    PubMed  CAS  Google Scholar 

  30. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ (2005) Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 92:342–349

    PubMed  CAS  Google Scholar 

  31. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1991) Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 147:4019–4026

    PubMed  CAS  Google Scholar 

  32. Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K (1991) Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 147:1091–1097

    PubMed  CAS  Google Scholar 

  33. Moreno MB, Titus JA, Cole MS, Tso JY, Le N, Paik CH, Bakacs T, Zacharchuk CM, Segal DM, Wunderlich JR (1995) Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. Cancer Immunol Immunother 40:182–190

    Article  PubMed  CAS  Google Scholar 

  34. Penna C, Dean PA, Nelson H (1994) Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res 54:2738–2743

    PubMed  CAS  Google Scholar 

  35. Bakacs T, Lee J, Moreno MB, Zacharchuk CM, Cole MS, Tso JY, Paik CH, Ward JM, Segal DMA (1995)bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Int Immunol 7:947–955

    Article  PubMed  CAS  Google Scholar 

  36. Grosse-Hovest L, Brandl M, Dohlsten M, Kalland T, Wilmanns W, Jung G (1999) Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28. Int J Cancer 80:138–144

    Article  PubMed  CAS  Google Scholar 

  37. Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98:2526–2534

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Micromet AG, Staffelseestr 2, 81477, Munich, Germany

    Bernd Schlereth, Petra Kleindienst, Grit Lorenczewski, Klaus Brischwein, Sandra Lippold, Antonio da Silva, Mathias Locher, Roman Kischel, Ralf Lutterbüse, Peter Kufer & Patrick A. Baeuerle

  2. Experimental Pharmacology and Oncology (EPO), 13122, Berlin-Buch, Germany

    Iduna Fichtner

Authors
  1. Bernd Schlereth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petra Kleindienst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iduna Fichtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Grit Lorenczewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Klaus Brischwein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sandra Lippold
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mathias Locher
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roman Kischel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ralf Lutterbüse
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Peter Kufer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Patrick A. Baeuerle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Schlereth.

Additional information

Bernd Schlereth and Petra Kleindienst contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlereth, B., Kleindienst, P., Fichtner, I. et al. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother 55, 785–796 (2006). https://doi.org/10.1007/s00262-005-0082-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0082-x

Keywords

Search

Navigation